Claudio N. Soares
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claudio N. Soares has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Meir Steiner
Women's Health Concerns Clinic, St. Joseph's Healthcare, Hamilton, ON, Canada
4 shared publications - Benicio Noronha Frey
McMaster University
3 shared publications - Geoffrey B. C. Hall
Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, ON, Canada
2 shared publications - Ana Cristina Andreazza
Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada
1 shared publication - Anastasiya Slyepchenko
MiNDS Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada
1 shared publication - Anthony L. Vaccarino
Indoc Research, Toronto, Canada
1 shared publication
Latest Publications
- Open Access
- 4 November 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 33 (3) , 261-269
The burden of sleep disturbances on quality of life and mental well-being in nearly 50,000 perimenopausal and postmenopausal women with and without concurrent vasomotor symptoms from the United States and Europe
Objectives: To quantify the burden of sleep disturbances on health-related quality of life (HRQoL) and mental well-being in perimenopausal and postmenopausal women with/without co-occurring vasomotor symptoms (VMS). Methods: Perimenopausal and postmenopausal women aged 40 to 65 years who participated in the National Health and Wellness 2019/2021 (US; N=27,621) and 2017/2020 cross-sectional surveys (France, Germany, Italy, Spain, UK; N=20,220) were included. Patient-reported outcomes were HRQoL (Short-Form Health Survey physical and mental component summary scores, EuroQol Visual Analogue Scale, EQ-5D-5L), depression (Patient Health Questionnaire-9), and anxiety (Generalized Anxiety Disorder-7 assessment). Associations between self-reported sleep disturbances and/or VMS and study outcomes were evaluated using generalized multivariable linear regression. Results: Among perimenopausal women, sleep disturbances were reported by 61.7% (US) and 60.6% (Europe) with VMS, and 38.0% (US) and 40.8% (Europe) without VMS. Among postmenopausal women, sleep disturbances were reported by 66.7% (US) and 63.4% (Europe) with VMS, and 44.5% (US) and 40.9% (Europe) without VMS. Compared with women with neither symptom, perimenopausal and postmenopausal women with sleep disturbances had worse HRQoL ( P P P P <0.001). Conclusions: Sleep disturbance was common among perimenopausal and postmenopausal women irrespective of VMS, and independently associated with negative effects on HRQoL, depression, and anxiety. Effective treatments for sleep disturbances and VMS in menopausal women are needed to mitigate the associated burden and improve well-being.
- 4 November 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 33 (3) , 261-269
Open AccessThe burden of sleep disturbances on quality of life and mental well-being in nearly 50,000 perimenopausal and postmenopausal women with and without concurrent vasomotor symptoms from the United States and Europe
Objectives: To quantify the burden of sleep disturbances on health-related quality of life (HRQoL) and mental well-being in perimenopausal and postmenopausal women with/without co-occurring vasomotor symptoms (VMS). Methods: Perimenopausal and postmenopausal women aged 40 to 65 years who participated in the National Health and Wellness 2019/2021 (US; N=27,621) and 2017/2020 cross-sectional surveys (France, Germany, Italy, Spain, UK; N=20,220) were included. Patient-reported outcomes were HRQoL (Short-Form Health Survey physical and mental component summary scores, EuroQol Visual Analogue Scale, EQ-5D-5L), depression (Patient Health Questionnaire-9), and anxiety (Generalized Anxiety Disorder-7 assessment). Associations between self-reported sleep disturbances and/or VMS and study outcomes were evaluated using generalized multivariable linear regression. Results: Among perimenopausal women, sleep disturbances were reported by 61.7% (US) and 60.6% (Europe) with VMS, and 38.0% (US) and 40.8% (Europe) without VMS. Among postmenopausal women, sleep disturbances were reported by 66.7% (US) and 63.4% (Europe) with VMS, and 44.5% (US) and 40.9% (Europe) without VMS. Compared with women with neither symptom, perimenopausal and postmenopausal women with sleep disturbances had worse HRQoL ( P P P P <0.001). Conclusions: Sleep disturbance was common among perimenopausal and postmenopausal women irrespective of VMS, and independently associated with negative effects on HRQoL, depression, and anxiety. Effective treatments for sleep disturbances and VMS in menopausal women are needed to mitigate the associated burden and improve well-being.
- 1 October 2024
- Published by Wolters Kluwer Health in Menopause
- Vol. 31 (10) , 839-841
PTSD in midlife women: when deconstructing improves screening and influences care
- 1 October 2024
- Published by Wolters Kluwer Health in Menopause
- Vol. 31 (10) , 839-841
PTSD in midlife women: when deconstructing improves screening and influences care
- 29 June 2022
- Published by Wolters Kluwer Health in Menopause
- Vol. 29 (7) , 765-766
Reflecting on the enduring effects of childhood maltreatment
- 29 June 2022
- Published by Wolters Kluwer Health in Menopause
- Vol. 29 (7) , 765-766
Reflecting on the enduring effects of childhood maltreatment
- 1 March 2017
- Published by Elsevier in Psychiatry Research
- Vol. 249, 354-362
Subtle persistent working memory and selective attention deficits in women with premenstrual syndrome
- 1 March 2017
- Published by Elsevier in Psychiatry Research
- Vol. 249, 354-362
Subtle persistent working memory and selective attention deficits in women with premenstrual syndrome
- Open Access
- 16 April 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 1-13
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers (“biomarkers”) of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10–20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2–10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. ClinicalTrials.gov identifier NCT01655706 . Registered July 27, 2012.
- 16 April 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 1-13
Open AccessDiscovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers (“biomarkers”) of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD. CAN-BIND-1 is a multisite initiative involving 6 academic health centres working collaboratively with other universities and research centres. In the 16-week protocol, patients with MDD are treated with a first-line antidepressant (escitalopram 10–20 mg/d) that, if clinically warranted after eight weeks, is augmented with an evidence-based, add-on medication (aripiprazole 2–10 mg/d). Comprehensive datasets are obtained using clinical rating scales; behavioural, dimensional, and functioning/quality of life measures; neurocognitive testing; genomic, genetic, and proteomic profiling from blood samples; combined structural and functional magnetic resonance imaging; and electroencephalography. De-identified data from all sites are aggregated within a secure neuroinformatics platform for data integration, management, storage, and analyses. Statistical analyses will include multivariate and machine-learning techniques to identify predictors, moderators, and mediators of treatment response. From June 2013 to February 2015, a cohort of 134 participants (85 outpatients with MDD and 49 healthy participants) has been evaluated at baseline. The clinical characteristics of this cohort are similar to other studies of MDD. Recruitment at all sites is ongoing to a target sample of 290 participants. CAN-BIND will identify biomarkers of treatment response in MDD through extensive clinical, molecular, and imaging assessments, in order to improve treatment practice and clinical outcomes. It will also create an innovative, robust platform and database for future research. ClinicalTrials.gov identifier NCT01655706 . Registered July 27, 2012.
- 26 January 2016
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 19 (1) , 1
Letter from the Editors
- 26 January 2016
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 19 (1) , 1
Letter from the Editors
- 26 February 2014
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 19 (6) , 519-527
Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder
Background: The predictive value of early functional improvement for treatment success at week 8 was assessed in a pooled analysis in patients with major depressive disorder (MDD).Methods: Data were pooled from 7 double-blind studies in adult patients with MDD randomly assigned to desvenlafaxine 50 mg/d or placebo. Four levels of treatment success were determined at week 8 for patients with baseline Sheehan Disability Scale (SDS) score > 12 (N = 2156): functional response (SDS ≤12 and ≥50% improvement in SDS), functional/depression response (SDS ≤12 and ≥50% improvement in both SDS and 17-item Hamilton Rating Scale for Depression [HAM-D17] score), functional remission (SDS < 7), and functional/depression remission (SDS < 7 and HAM-D17 ≤7). Week 2 improvement in SDS was evaluated as a predictor of later functional response/remission using receiver operating characteristic analysis. Odds ratios (ORs) of the predictability of improvement thresholds were computed from a logistic regression model.Results: The proportion of patients achieving each level of treatment success was significantly greater for patients treated with desvenlafaxine (40%, 32%, 23%, 15%, respectively) vs placebo (31%, 22%, 17%, 10%; all P ≤ 0.002). Early change in SDS was a highly significant predictor of functional response/remission (ORs, 0.958–0.970; all P < 0.0001).Discussion: Patients’ early functional response to desvenlafaxine 50 mg/d is predictive of treatment success.
- 26 February 2014
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 19 (6) , 519-527
Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder
Background: The predictive value of early functional improvement for treatment success at week 8 was assessed in a pooled analysis in patients with major depressive disorder (MDD).Methods: Data were pooled from 7 double-blind studies in adult patients with MDD randomly assigned to desvenlafaxine 50 mg/d or placebo. Four levels of treatment success were determined at week 8 for patients with baseline Sheehan Disability Scale (SDS) score > 12 (N = 2156): functional response (SDS ≤12 and ≥50% improvement in SDS), functional/depression response (SDS ≤12 and ≥50% improvement in both SDS and 17-item Hamilton Rating Scale for Depression [HAM-D17] score), functional remission (SDS < 7), and functional/depression remission (SDS < 7 and HAM-D17 ≤7). Week 2 improvement in SDS was evaluated as a predictor of later functional response/remission using receiver operating characteristic analysis. Odds ratios (ORs) of the predictability of improvement thresholds were computed from a logistic regression model.Results: The proportion of patients achieving each level of treatment success was significantly greater for patients treated with desvenlafaxine (40%, 32%, 23%, 15%, respectively) vs placebo (31%, 22%, 17%, 10%; all P ≤ 0.002). Early change in SDS was a highly significant predictor of functional response/remission (ORs, 0.958–0.970; all P < 0.0001).Discussion: Patients’ early functional response to desvenlafaxine 50 mg/d is predictive of treatment success.
- 26 June 2013
- Published by Springer Nature in Drugs & Aging
- Vol. 30 (9) , 677-685
Depression in Peri- and Postmenopausal Women: Prevalence, Pathophysiology and Pharmacological Management
Epidemiologic and clinic data have unequivocally supported the notion that women experience more psychiatric problems at some point in their lives compared with men, particularly mood and anxiety symptoms and sleep problems. It is also known that, for some women, such increased risk might be associated with reproductive cycle events such as the postpartum period or the menopausal transition. These periods are not only marked by substantial hormone variations but also quite often accompanied by stressful events and changes in personal, family and professional responsibilities. The complexity of these reproductive-related ‘windows of vulnerability’ poses a challenge to physicians and other professionals dedicated to women’s health across the lifespan. The menopausal transition and early postmenopausal years constitute a characteristic example; during this period in life, dynamic changes in sex hormones and reproductive function co-occur with modifications in metabolism, sexuality, lifestyle behaviours and overall health, sometimes affecting a woman’s quality of life and overall functioning. For most women, however, this transition has little or no significant impact on their mental wellness. A prior depressive episode—particularly if related to reproductive events—is the strongest predictor of mood symptoms or depression during menopausal years. Also, the presence and severity of vasomotor symptoms and other health-related issues appear to modulate the risk for depression in midlife women. Mechanistically, estrogen plays an important modulatory role in mood and cognitive regulation, hence the effects noted when midlife women are exposed to significant estrogen fluctuations or to estrogen-based therapies (use or withdrawal). Transdermal estradiol, as well as serotonergic and noradrenergic antidepressants, have shown efficacy in the management of depression in this population. Other evidence-based treatment options (hormonal, pharmacological, behavioural) are available to clinicians and health professionals who care for this population.
- 26 June 2013
- Published by Springer Nature in Drugs & Aging
- Vol. 30 (9) , 677-685
Depression in Peri- and Postmenopausal Women: Prevalence, Pathophysiology and Pharmacological Management
Epidemiologic and clinic data have unequivocally supported the notion that women experience more psychiatric problems at some point in their lives compared with men, particularly mood and anxiety symptoms and sleep problems. It is also known that, for some women, such increased risk might be associated with reproductive cycle events such as the postpartum period or the menopausal transition. These periods are not only marked by substantial hormone variations but also quite often accompanied by stressful events and changes in personal, family and professional responsibilities. The complexity of these reproductive-related ‘windows of vulnerability’ poses a challenge to physicians and other professionals dedicated to women’s health across the lifespan. The menopausal transition and early postmenopausal years constitute a characteristic example; during this period in life, dynamic changes in sex hormones and reproductive function co-occur with modifications in metabolism, sexuality, lifestyle behaviours and overall health, sometimes affecting a woman’s quality of life and overall functioning. For most women, however, this transition has little or no significant impact on their mental wellness. A prior depressive episode—particularly if related to reproductive events—is the strongest predictor of mood symptoms or depression during menopausal years. Also, the presence and severity of vasomotor symptoms and other health-related issues appear to modulate the risk for depression in midlife women. Mechanistically, estrogen plays an important modulatory role in mood and cognitive regulation, hence the effects noted when midlife women are exposed to significant estrogen fluctuations or to estrogen-based therapies (use or withdrawal). Transdermal estradiol, as well as serotonergic and noradrenergic antidepressants, have shown efficacy in the management of depression in this population. Other evidence-based treatment options (hormonal, pharmacological, behavioural) are available to clinicians and health professionals who care for this population.
- Open Access
- 1 January 2013
- Published by Springer Nature in Biology of Sex Differences
- Vol. 4 (1) , 7
Steroid concentrations in antepartum and postpartum saliva: normative values in women and correlations with serum
Saliva has been advocated as an alternative to serum or plasma for steroid monitoring. Little normative information is available concerning expected concentrations of the major reproductive steroids in saliva during pregnancy and the extended postpartum. Matched serum and saliva specimens controlled for time of day and collected less than 30 minutes apart were obtained in 28 women with normal singleton pregnancies between 32 and 38 weeks of gestation and in 43 women during the first six months postpartum. Concentrations of six steroids (estriol, estradiol, progesterone, testosterone, cortisol, dehydroepiandrosterone) were quantified in saliva by enzyme immunoassay. For most of the steroids examined, concentrations in antepartum saliva showed linear increases near end of gestation, suggesting an increase in the bioavailable hormone component. Observed concentrations were in agreement with the limited data available from previous reports. Modal concentrations of the ovarian steroids were undetectable in postpartum saliva and, when detectable in individual women, approximated early follicular phase values. Only low to moderate correlations between the serum and salivary concentrations were found, suggesting that during the peripartum period saliva provides information that is not redundant to serum. Low correlations in the late antepartum may be due to differential rates of change in the total and bioavailable fractions of the circulating steroid in the final weeks of the third trimester as a consequence of dynamic changes in carrier proteins such as corticosteroid binding globulin.
- 1 January 2013
- Published by Springer Nature in Biology of Sex Differences
- Vol. 4 (1) , 7
Open AccessSteroid concentrations in antepartum and postpartum saliva: normative values in women and correlations with serum
Saliva has been advocated as an alternative to serum or plasma for steroid monitoring. Little normative information is available concerning expected concentrations of the major reproductive steroids in saliva during pregnancy and the extended postpartum. Matched serum and saliva specimens controlled for time of day and collected less than 30 minutes apart were obtained in 28 women with normal singleton pregnancies between 32 and 38 weeks of gestation and in 43 women during the first six months postpartum. Concentrations of six steroids (estriol, estradiol, progesterone, testosterone, cortisol, dehydroepiandrosterone) were quantified in saliva by enzyme immunoassay. For most of the steroids examined, concentrations in antepartum saliva showed linear increases near end of gestation, suggesting an increase in the bioavailable hormone component. Observed concentrations were in agreement with the limited data available from previous reports. Modal concentrations of the ovarian steroids were undetectable in postpartum saliva and, when detectable in individual women, approximated early follicular phase values. Only low to moderate correlations between the serum and salivary concentrations were found, suggesting that during the peripartum period saliva provides information that is not redundant to serum. Low correlations in the late antepartum may be due to differential rates of change in the total and bioavailable fractions of the circulating steroid in the final weeks of the third trimester as a consequence of dynamic changes in carrier proteins such as corticosteroid binding globulin.
- 11 November 2012
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 16 (1) , 83-85
Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder
Depression during midlife years may lead to significant sleep disturbances and adversely impact quality of life (QOL). In this report, we examined the effects of treatment with quetiapine extended release (XR), 150–300 mg/day, on sleep and QOL in 23 midlife women with major depressive disorder (MDD). Quetiapine XR improved subjective sleep distress, overall sleep parameters, and sleep-related QOL, ultimately leading to significant improvement in menopause-related QOL. While larger, controlled trials are still awaited, these preliminary results are encouraging and suggest that quetiapine XR may be a useful tool in treating symptomatic midlife women with MDD.
- 11 November 2012
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 16 (1) , 83-85
Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder
Depression during midlife years may lead to significant sleep disturbances and adversely impact quality of life (QOL). In this report, we examined the effects of treatment with quetiapine extended release (XR), 150–300 mg/day, on sleep and QOL in 23 midlife women with major depressive disorder (MDD). Quetiapine XR improved subjective sleep distress, overall sleep parameters, and sleep-related QOL, ultimately leading to significant improvement in menopause-related QOL. While larger, controlled trials are still awaited, these preliminary results are encouraging and suggest that quetiapine XR may be a useful tool in treating symptomatic midlife women with MDD.